Stayble Therapeutics
Stayble Therapeutics AB is a Swedish clinical-stage biopharmaceutical company based in Gothenburg. It develops STA363, an injectable treatment concept for pain caused by herniated disc, with the aim of addressing the underlying cause of symptoms rather than only providing temporary relief.
Fiscal year 2024 · change from previous year
Development 2023–2024
Business
Share of revenueDevelopment of STA363 as a treatment for pain caused by herniated disc.
Clinical study work to test safety, efficacy, and dosing of the candidate.
Potential future out-licensing or partnering of the treatment concept.
Customers
Stayble does not appear to sell a commercial product yet; its near-term counterparties are clinical trial participants, investigators, and development partners. In a future commercial model, the end users would be patients with persistent pain after disc herniation, while buyers would likely include healthcare providers, hospitals, and potentially licensed pharmaceutical partners.
Patients enrolled to evaluate STA363 safety and efficacy in disc-related pain.
Hospitals and research centers that administer the study protocol and collect data.
Pharmaceutical or biotech companies that may acquire rights to develop or commercialize STA363.
Healthcare providers that would prescribe or administer the treatment if approved.
Strategy
Stayble’s strategy is centered on advancing STA363 through clinical development and building evidence that the treatment can address disc-related pain with a simple, one-time injection. The company also emphasizes using an existing active substance, which can shorten development timelines and support future partnering or licensing discussions.
Clinical data is the main value driver for a pre-commercial biotech company.
A simple treatment profile can improve adoption and partnering appeal.
External partners may be needed to fund late-stage development and market access.
Geography
Stayble is headquartered in Gothenburg, Sweden, and its corporate and development activities are anchored there. The available reports do not disclose a commercial revenue geography, which is consistent with a development-stage company whose operations are centered on Sweden and external clinical development partners.
Risks
Stayble is exposed to the classic risks of a clinical-stage biotech company: funding needs, uncertain trial outcomes, and dependence on third-party development partners. Because it does not yet generate product sales, setbacks in clinical development or capital raising could materially affect its ability to continue operations.
- Financing riskImpact: CriticalLikelihood: Medium
The company has no approved treatment generating sales and must fund ongoing development.
Exposure: Clinical development and corporate overhead
- Clinical trial riskImpact: HighLikelihood: Medium
Drug development depends on proving safety and efficacy in human studies.
Exposure: STA363 development program
- Regulatory approval riskImpact: HighLikelihood: Medium
Even promising clinical data may not translate into marketing authorization.
Exposure: Future commercialization pathway
- Partner dependency riskImpact: High
Development and future commercialization may rely on external collaborators.
Exposure
Accounting
Judgemental itemsClinical-stage biotech spending is usually expensed as incurred and drives reported losses.
Impact: Affects operating result and comparability across periods
Trial services are often recognized before invoices are received.
Impact: Can shift expenses between quarters
A pre-revenue company must assess whether it can fund future operations.
Impact: Affects disclosure and valuation of the business
Development-related assets or costs may require judgment on recoverability.
Impact: Can materially affect balance sheet and earnings
Similar listed companies
Publicly listed companies with a comparable business focus.
Stoke Therapeutics, Inc.
STOK · Pharmaceutical Preparations
Enanta Pharmaceuticals, Inc
ENTA · Pharmaceutical Preparations
Enanta Pharmaceuticals is a U.S.-based biotechnology company focused on discovering and developing small-molecule drugs in virology and immunology.
Vera Therapeutics, Inc.
VERA · Pharmaceutical Preparations
Century Therapeutics, Inc.
IPSC · Biological Products, (No Diagnostic Substances)
Milestone Scientific, Inc
MLSS · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Spyre Therapeutics, Inc.
SYRE · Pharmaceutical Preparations
Spyre Therapeutics is a U.S.-based clinical-stage biotechnology company focused on developing long-acting antibody therapies for inflammatory bowel disease and rheumatic diseases.
Last updated: 24/09/2026